Posts From August, 2019

Pravin U. Dugel, MD: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD

OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to… Read More »


Pravin U. Dugel MD: Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema

Presented in part at: 15th Annual Angiogenesis, Exudation, and Degeneration meeting, February 2018, Miami, Florida; 41st Annual Macula Society Meeting, February 2018, Beverly Hills, California; Association for Research in Vision and Ophthalmology Annual Meeting, April–May 2018, Honolulu, Hawaii; Royal College of Ophthalmologists Annual Congress 2018, May 2018, Liverpool, United Kingdom; 36th World Ophthalmology Congress, June… Read More »